JP4303969B2 - Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン - Google Patents

Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン Download PDF

Info

Publication number
JP4303969B2
JP4303969B2 JP2002577784A JP2002577784A JP4303969B2 JP 4303969 B2 JP4303969 B2 JP 4303969B2 JP 2002577784 A JP2002577784 A JP 2002577784A JP 2002577784 A JP2002577784 A JP 2002577784A JP 4303969 B2 JP4303969 B2 JP 4303969B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
methyl
group
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002577784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004524360A (ja
JP2004524360A5 (https=
Inventor
ジョン ダブリュー． クレイダー，
スー−イング ワイ． リン，
スチュアート ダブリュー． マックコンビー，
プラディープ ビー． プッシュパヴァナム，
スーザン バイス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004524360A publication Critical patent/JP2004524360A/ja
Publication of JP2004524360A5 publication Critical patent/JP2004524360A5/ja
Application granted granted Critical
Publication of JP4303969B2 publication Critical patent/JP4303969B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002577784A 2001-03-29 2002-03-27 Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン Expired - Fee Related JP4303969B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995001P 2001-03-29 2001-03-29
PCT/US2002/009490 WO2002079157A1 (en) 2001-03-29 2002-03-27 Aryl oxime-piperazines useful as ccr5 antagonists

Publications (3)

Publication Number Publication Date
JP2004524360A JP2004524360A (ja) 2004-08-12
JP2004524360A5 JP2004524360A5 (https=) 2009-01-22
JP4303969B2 true JP4303969B2 (ja) 2009-07-29

Family

ID=23071025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002577784A Expired - Fee Related JP4303969B2 (ja) 2001-03-29 2002-03-27 Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン

Country Status (18)

Country Link
US (1) US6689783B2 (https=)
EP (1) EP1373206B1 (https=)
JP (1) JP4303969B2 (https=)
KR (1) KR20030083015A (https=)
CN (1) CN1253435C (https=)
AR (1) AR033622A1 (https=)
AT (1) ATE418542T1 (https=)
AU (1) AU2002303168B2 (https=)
CA (1) CA2442210C (https=)
DE (1) DE60230491D1 (https=)
ES (1) ES2318009T3 (https=)
HU (1) HUP0400389A3 (https=)
IL (1) IL157713A0 (https=)
MX (1) MXPA03008801A (https=)
MY (1) MY134019A (https=)
NZ (1) NZ528011A (https=)
WO (1) WO2002079157A1 (https=)
ZA (1) ZA200307171B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) * 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
EP1725235B1 (en) * 2004-02-05 2009-04-15 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
US20070215685A1 (en) * 2005-02-03 2007-09-20 Yottamark, Inc. System and Method of Product Identification Using a URL
JP4769257B2 (ja) * 2005-02-23 2011-09-07 シェーリング コーポレイション ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
KR100830003B1 (ko) * 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법
US20080173808A1 (en) * 2007-01-18 2008-07-24 Schering Corporation Process and device for response normalized liquid chromatography nanospray ionization mass spectrometry (rnlc-nsi-ms)
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2021222441A1 (en) 2020-02-19 2022-09-22 Ichilov Tech Ltd. Improved antidepressant therapy
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
AU4788396A (en) 1995-02-16 1996-09-04 Children's Medical Center Corporation Inhibition of angiogenesis using interleukin-12
CA2371583C (en) * 1999-05-04 2005-09-13 Schering Corporation Piperazine derivatives useful as ccr5 antagonists

Also Published As

Publication number Publication date
CN1253435C (zh) 2006-04-26
HK1057211A1 (en) 2004-03-19
CN1500078A (zh) 2004-05-26
ATE418542T1 (de) 2009-01-15
HUP0400389A2 (hu) 2004-08-30
JP2004524360A (ja) 2004-08-12
DE60230491D1 (de) 2009-02-05
AR033622A1 (es) 2003-12-26
US20030087912A1 (en) 2003-05-08
US6689783B2 (en) 2004-02-10
CA2442210C (en) 2009-09-08
MY134019A (en) 2007-11-30
AU2002303168B2 (en) 2005-10-06
CA2442210A1 (en) 2002-10-10
NZ528011A (en) 2004-08-27
ES2318009T3 (es) 2009-05-01
IL157713A0 (en) 2004-03-28
ZA200307171B (en) 2004-12-13
EP1373206B1 (en) 2008-12-24
HUP0400389A3 (en) 2008-03-28
KR20030083015A (ko) 2003-10-23
EP1373206A1 (en) 2004-01-02
MXPA03008801A (es) 2004-02-18
WO2002079157A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
US8034933B2 (en) Piperidine derivatives useful as CCR5 antagonists
JP4248251B2 (ja) Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト
JP2006225407A (ja) Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
AU2002255947A1 (en) CCR5 antagonists useful for treating AIDS
JP4303969B2 (ja) Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン
AU2002303168A1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
CN1898231B (zh) 用作趋化因子受体抑制剂的双六氢吡啶衍生物
US7659275B2 (en) Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
US7705019B2 (en) Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
HK1057211B (en) Aryl oxime-piperazines useful as ccr5 antagonists
HK1057363B (en) Ccr5 antagonists useful for treating aids
HK1083505B (en) Ccr5 antagonists useful for treating aids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090421

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090427

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120501

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees